bims-rebome Biomed News
on Management of bone metastases
Issue of 2026–11–22
eight papers selected by
Alberto Selvanetti, Azienda Ospedaliera San Giovanni Addolorata



  1. Orthop Surg. 2026 Nov 17.
      Accurate survival estimation fundamentally guides treatment strategy for metastatic bone disease, balancing durable surgical reconstruction against palliative care. Over three decades, predictive tools have evolved from static classical scores into sophisticated nomograms and machine learning algorithms, integrating patient reserve, tumor biology, metastatic burden, and treatment context. In this comprehensive review, we systematically searched PubMed, Embase, and Web of Science and identified 25 studies reporting the development or external validation of multivariable survival prediction models, encompassing classical scoring systems (Tokuhashi, Tomita, Bauer, Katagiri), nomograms (SORG), Bayesian networks (PATHFx), and machine learning algorithms (SORG-MLA, BMETS). While this methodological evolution improved individualized prognostication in derivation cohorts, external validation studies reveal a critical disconnect: algorithmic complexity does not guarantee clinical transportability. Our synthesis identifies several recurrent sources of this transportability failure, primarily temporal calibration drift from evolving systemic therapies, anatomic site mismatches between spinal and appendicular disease, and selection biases inherent to surgical versus radiotherapeutic cohorts. Consequently, a substantial gap persists between methodological sophistication and actual bedside applicability, and routine clinical deployment of these tools remains premature until these foundational deficits are systematically addressed. Bridging this gap requires shifting from universal prediction tools toward context-specific, prospectively validated models with routine temporal recalibration.
    Keywords:  bone metastasis; machine learning; orthopedic oncology; prognostic model; spine metastasis; survival prediction
    DOI:  https://doi.org/10.1111/os.70463
  2. Front Immunol. 2026 ;17 1982392
      Bone metastases develop within a mineralized and hematopoietic environment shaped by continuous skeletal remodeling, immune-cell trafficking, and systemic host physiology. This specialized niche can restrict immune checkpoint blockade, but the factors governing its responsiveness remain incompletely defined. Evidence linking nutritional status and related endocrine or metabolic factors to bone-specific immunity is fragmented across osteoimmunology, tumor immunology, nutrition, endocrinology, and translational oncology. We distinguish direct nutritional exposures from host-state indices, mineral endocrine regulators, and microbiome-derived metabolites. Mechanistic studies identify osteoclast-associated pathways, including RANK-RANKL signaling and osteopontin, as direct links between skeletal remodeling, impaired T-cell recruitment, and experimental resistance to checkpoint blockade. By contrast, albumin-based indices, cachexia, anemia-related measures, glucocorticoid exposure, thyroid dysfunction, and microbiome features generally provide prognostic, treatment-related, or associative evidence across heterogeneous cancer cohorts. They do not establish ICI-specific prediction, causal reversibility, or therapeutic benefit. Clinical evidence for combining checkpoint inhibitors with antiresorptive, nutritional, endocrine, or microbiome interventions remains inconsistent or preliminary. We therefore use the nutrition-bone-immune axis as a conceptual, evidence-organizing framework, not as a clinically validated unified causal pathway. Clinical translation will require prospective bone-specific cohorts, paired systemic and lesion-level profiling, rigorous temporal definitions, treatment-interaction analyses, and randomized trials integrating skeletal, immune, and oncological endpoints.
    Keywords:  bone metastases; immune checkpoint blockade; immune microenvironment of bone metastases; nutritional status; osteoimmunology
    DOI:  https://doi.org/10.3389/fimmu.2026.1982392
  3. Front Endocrinol (Lausanne). 2026 ;17 1806427
       Background: Bone-modifying agents (BMAs) represent standard supportive therapy for patients with bone metastases to mitigate skeletal-related events (SREs). Alongside improved cancer survival, cumulative antiresorptive exposure renders atypical femoral fracture (AFF) an important yet infrequent complication. For patients with active metastatic disease, clinical management poses unique challenges, since discontinuation of antiresorptive agents may elevate skeletal-related risk while sustained suppression may impede fracture healing.
    Case presentation: A 56-year-old postmenopausal woman with metastatic breast cancer had received zoledronic acid (4 mg intravenously every 3 months) for 4 years. Because of progression of bone metastases and chest/back pain, treatment was changed to denosumab (120 mg monthly). After three doses, she developed bilateral thigh pain after a minor torsion injury, and radiographs demonstrated bilateral transverse femoral shaft fractures with lateral cortical thickening. Bilateral antegrade intramedullary nailing was performed. Intraoperative bone marrow pathology showed no tumor infiltration. Denosumab was discontinued. Two months later, because of persistent severe osteoporosis and increased bone resorption (β-CTX 0.65 ng/mL), zoledronic acid 4 mg every 12 weeks was restarted.
    Outcome: Eight months after fixation, both fractures achieved radiographic healing with callus formation; no new skeletal-related events were documented during follow-up. Serum β-CTX decreased to 0.35 ng/mL. This clinical course suggests that de-escalated zoledronic acid therapy was temporally associated with fracture healing while sustaining continuous antiresorptive effects in this individual patient.
    Conclusion: This case underscores the diagnostic necessity of distinguishing AFF from metastatic pathological fracture, as well as the therapeutic trade-off between fracture healing and sustained skeletal protection. Sequential antiresorptive exposure, notably prolonged bisphosphonate administration followed by denosumab, warrants vigilant clinical screening for potential AFF. Post-denosumab therapeutic strategies should take rebound bone turnover into consideration. The proposed risk-stratified surveillance framework is evidence-informed but remains unvalidated and should not be interpreted as formal clinical guidance.
    Keywords:  atypical femoral fracture; bone-modifying agent; breast cancer metastasis; denosumab; risk stratification; zoledronic acid
    DOI:  https://doi.org/10.3389/fendo.2026.1806427
  4. Adv Radiat Oncol. 2026 Nov;11(11): 102148
       Purpose: Outcomes after repeat stereotactic body radiation therapy (SBRT2) for spinal metastases progressing after prior SBRT (SBRT1) remain incompletely defined. We evaluated local control (LC), overall survival (OS), pain response, toxicity, and predictors of outcome after salvage SBRT2.
    Methods and Materials: Patients treated with SBRT2 for in-field failure or adjacent-level progression after SBRT1 between January 2018 and October 2025 were retrospectively reviewed. The primary endpoint was LC. Secondary endpoints included OS, pain response, toxicity, and predictors of outcome. LC was analyzed using cumulative incidence and Fine-Gray regression, and OS was estimated using Kaplan-Meier analysis. Target dose heterogeneity was assessed using the minimum target dose (Dmin 0.03 cc).
    Results: Forty-nine patients underwent SBRT2 to 115 vertebral segments. Median OS was 17.6 months, with 6- and 12-month OS rates of 76% and 57%. Disease extent strongly influenced survival. Patients with oligometastatic disease had longer OS than those with extensive disease (31.6 vs 7.4 months; 12-month OS, 88% vs 36%; P < .001). The cumulative incidence of local failure was 15% at 6 months and 25% at 12 months. A higher delivered target dose was associated with improved LC. Patients treated to Dmin ≥28 Gy had lower 12-month local failure than those treated to <28 Gy (6% vs 36%; Gray's P = .034). Increasing Dmin was associated with reduced risk of local failure (SHR 0.27; P = .029). Patients with oligometastatic disease demonstrated lower local failure (6- and 12-month incidence, 6% and 12%). Among patients with baseline pain, complete or partial response at 3 months occurred in 55%, with a durable response in 46%. No radiation-induced myelopathy occurred. Crude vertebral compression fracture rate was 12%.
    Conclusions: Repeat spine SBRT provides acceptable early LC and meaningful pain relief in selected patients. Outcomes appear most favorable in patients with oligometastatic disease. LC after SBRT2 was associated with minimum target dose, supporting careful patient selection and salvage treatment planning.
    DOI:  https://doi.org/10.1016/j.adro.2026.102148
  5. Drugs Context. 2026 ;pii: 2026-6-11. [Epub ahead of print]15
      Metastatic renal cell carcinoma (mRCC) presents with marked biological heterogeneity, and bone involvement is associated with aggressive disease and limited response to systemic therapies. We report the case of a 33-year-old female patient with clear cell mRCC who developed metastatic progression after undergoing curative-intent surgery, presenting with vertebral bone metastasis at C7 and peritoneal carcinomatosis. First-line treatment with pembrolizumab plus lenvatinib was initiated, leading to a deep and durable response. A radiological complete response was achieved at all metastatic sites, and subsequent surgery confirmed histological complete remission in the bone lesion. Pathologically documented complete responses in bone metastases from RCC are remarkably rare. This case highlights the potential of immune-checkpoint inhibitor-tyrosine kinase inhibitor combinations to induce profound responses even in unfavourable metastatic patterns and supports a multidisciplinary treatment strategy.
    Keywords:  bone metastases; complete response; immunotherapy-TKI combination; multidisciplinary management; renal cell carcinoma
    DOI:  https://doi.org/10.7573/dic.2026-6-11
  6. Breast Cancer. 2026 Nov 19.
       BACKGROUND: The effects of discontinuing oncology-dose denosumab on bone mineral density (BMD) remain unclear. We investigated longitudinal BMD changes after discontinuation in patients with metastatic breast cancer.
    METHODS: We conducted a single-center retrospective longitudinal cohort study of 72 women with breast cancer and bone metastases who discontinued treatment with denosumab 120 mg. An exploratory breast cancer control cohort without bone metastases or prior denosumab exposure, frequency-matched by age at the group level (n = 32), was also evaluated. BMD at the lumbar spine and proximal femur was quantified from routine non-contrast computed tomography (CT) using an artificial intelligence-driven pipeline, and changes from baseline were assessed at prespecified intervals of 3, 6, 9, 12, 18, and 24 months. Skeletal-related events (SREs) before and after discontinuation were also evaluated. Changes were analyzed using linear mixed-effects models with categorical follow-up time and random intercepts.
    RESULTS: Medication-related osteonecrosis of the jaw was the most common reason for denosumab discontinuation (75.0%). BMD declined over time at both sites, with significant reductions at 12, 18, and 24 months of 7.0%, 10.2%, and 11.3% at the lumbar spine and 3.8%, 10.0%, and 10.7% at the proximal femur, respectively. In the exploratory control cohort, median 24-month BMD changes were - 1.6% (proximal femur) and - 3.2% (lumbar spine). Post-discontinuation SREs occurred in 12 patients (16.7%), seven of whom had no prior SRE.
    CONCLUSIONS: Discontinuation of oncology-dose denosumab was followed by time-dependent CT-derived BMD loss at both sites, with significant reductions from 12 months onward. Prospective studies are needed to clarify the clinical implications and optimal post-discontinuation management.
    Keywords:  Bone metastasis; Bone mineral density; Breast cancer; Computed tomography; Denosumab
    DOI:  https://doi.org/10.1007/s12282-026-01943-3
  7. Tech Innov Patient Support Radiat Oncol. 2026 Dec;40 100452
       Background and purpose: Patients receiving palliative radiotherapy for spinal metastases often have severe pain, which may impair positional stability during treatment. We evaluated whether pain severity is associated with setup error, and estimated setup margins stratified by spinal level and immobilization method.
    Materials and methods: This secondary analysis used data from a prospective cohort (UMIN000044984) of patients who underwent three-dimensional conformal spinal radiotherapy at our institution. Only sites with pre-treatment CBCT and a recorded baseline numerical rating scale (NRS) pain score were included (376 sites, 270 patients). The three-dimensional vector setup error was calculated as √(SI2 + LR2 + AP2), where SI, LR, and AP denote the superior-inferior, left-right, and anterior-posterior translational errors. Pain was categorized as mild (NRS 0-4), moderate (5-6), or severe (7-10). Associations with setup error were assessed by the Kruskal-Wallis test and Spearman correlation. Setup margins were estimated using both |mean| + 2SD and |mean| + 3SD criteria per direction, stratified by spinal level and immobilization method.
    Results: Median 3D vector setup error was 0.52 cm (IQR, 0.36-0.75). Setup error did not differ across pain groups (Kruskal-Wallis P = 0.134; Spearman r = 0.088, P = 0.089). Spinal level was the main associated factor: cervical treatments (thermoplastic mask) had lower median error than thoracolumbar/sacral (TLS) treatments without immobilization (0.41 vs. 0.54 cm, P = 0.004). Estimated margins were approximately 1.0 cm (cervical) and 1.5 cm (TLS).
    Conclusions: Baseline pain severity was not associated with setup error in palliative spinal radiotherapy. Spinal level, which determined the immobilization method, was the factor most strongly associated with setup error. The proposed margins may serve as practical planning references, in settings without pre-treatment image guidance based on skin-mark alignment.
    Keywords:  Pain severity; Palliative radiotherapy; Patient positioning; Planning target volume margin; Setup error; Spinal metastases
    DOI:  https://doi.org/10.1016/j.tipsro.2026.100452
  8. J Vasc Interv Radiol. 2026 Nov 14. pii: S1051-0443(26)01211-X. [Epub ahead of print] 109200
       PURPOSE: To evaluate the incidence of secondary fractures after cryoablation of sclerotic or mixed-type metastases in the spine and pelvis without concurrent consolidation, and to identify associated risk factors.
    MATERIALS AND METHODS: A retrospective single-center analysis of 66 sclerotic or mixed-type metastases in the vertebral column or pelvis in 55 patients (median age 59 years, 45% men) treated with percutaneous cryoablation without simultaneous consolidation between 2018 and 2026 was performed. Follow-up cross-sectional imaging was assessed for evidence of fracture, and univariable logistic regression analysis was performed to identify patient-specific, procedural and radiographic characteristics associated with fracture occurrence. Candidate cut-offs were explored by ROC analysis.
    RESULTS: Over a median follow-up of 13 months, six fractures (9%) occurred in the treated area after a mean delay of 4.7 months (range 1-9 months). Five of six patients (83%) were symptomatic, and 4/6 (67%) required subsequent consolidation. Metastasis size (OR=1.32 per cm increase, 95% CI 1.01-1.75; p=0.046) and the number of cryoprobes (OR=2.93, CI 1.61-6.49; p<0.001) were significantly associated with fracture occurrence. In a sensitivity analysis restricted to one lesion per patient, the association with cryoprobe number remained robust, whereas that with size was attenuated. Exploratory cut-offs were 4 cryoprobes (AUC 0.846) and 5.8 cm (0.749).
    CONCLUSION: Isolated cryoablation of sclerotic or mixed-type metastases in the spine and pelvis carries an estimated fracture risk of ∼9%, increasing with metastasis size and the number of cryoprobes used. These findings may aid risk stratification and help to identify which patients could benefit from additional consolidation.
    DOI:  https://doi.org/10.1016/j.jvir.2026.109200